From Academic Innovation to a Clinical-Stage Oral Immunotherapy Platform
Our foundational technology, an oral T-cell immunotherapy platform, was developed at UC San Diego by Dr. Andreas Niethammer (Niethammer et al. 2002). His vision was to create a safe, convenient, and effective cancer therapy. Today, as VAXIMM’s Chief Executive Officer, Dr. Niethammer continues to guide this innovative research from the laboratory to patients in need.
Select Company Milestones
2008 - Company Foundation
VAXIMM was founded as a spin-out from UC San Diego, based on Dr. Andreas Niethammer's pioneering research into oral T-cell immunotherapy, and joint venture of BB Biotech Ventures and Merck KGaA.
2011 - First-in-Human Study for VXM01
VAXIMM initiated its first clinical trial, a Phase I dose escalation study, for VXM01. The study enrolled pancreatic cancer patients at Heidelberg University Hospital to evaluate the vaccine's safety, tolerability, and immunogenicity.
2017 - Key Clinical Partnership
A key clinical trial was launched to test VAXIMM's lead candidate, VXM01, in combination with the checkpoint inhibitor avelumab.
2018 - Strategic Licensing Agreement
A major licensing deal with China Medical System (CMS) expanded VAXIMM's reach, granting CMS rights to develop and commercialize products in Asia.
2022 - Acquisition and Growth
Acquired by BCM Europe AG, VAXIMM became a key subsidiary of OSR Holdings, Inc. (NASDAQ:OSRH), accelerating its mission to deliver next-gen therapies.
Team
Andreas Niethammer, MD, PhD
Chief Executive Officer
As the inventor of VAXIMM's core technology, Dr. Niethammer brings deep scientific expertise to his role as CEO. He is responsible for guiding the company's overarching strategy, transitioning his focus from clinical execution to leading VAXIMM's growth and operational success.
Advisors
Constance Höfer, PhD
Chief Scientific Officer, OSR Holdings
Dr. Höfer is a seasoned biopharma executive with a strong scientific foundation, holding a Ph.D. in Pharmacology from the University of Newcastle. Her career is marked by significant leadership roles, including serving as Global Program Head at both Merck Healthcare and Sandoz Biopharma. She also bring deep operational and development expertise from her time as COO of Priaxon AG and VP of Drug Development at Medigene AG.
Josh Pan, PhD
Venture Partner, OSR Holdings
Dr. Pan provides a dual perspective in science and business, holding both a Ph.D. in Molecular and Cellular Biology and an MBA from the University of Washington. He possesses extensive experience in venture capital and corporate strategy, having served as Partner at Bellevue Capital Management, Chief Operating Officer at the W Fund, Chief Business Officer at Landmark BioVentures, and Vice President of Corporate Development and External Affairs at Athira Pharma.
OSR Holdings
OSR Holdings, Inc. (NASDAQ:OSRH) is a healthcare group that operates on a hub-and-spoke model. The company focuses on partnering with biopharmaceuticals that have innovative R&D platforms. OSR Holdings’ current portfolio includes technologies in immuno-oncology, regenerative biologics, and medical devices. They leverage a global network across the US, Europe, and Korea to develop a wide range of healthcare solutions.
Careers
We are always looking for passionate and talented individuals to help advance our mission. We welcome open applications from professionals with expertise in key areas such as Regulatory Affairs, CMC (Chemistry, Manufacturing, and Controls), clinical development, and other related fields.
If you are interested in joining VAXIMM, please send your spontaneous application and CV to: careers@vaximm.com